Impact of a rapid multiplex polymerase chain reaction blood culture identification technology on outcomes in patients with vancomycin-resistant Enterococcal bacteremia.

Autor: MacVane SH; a Department of Pharmacy , Medical University of South Carolina , Charleston , SC , USA ;; b Division of Infectious Diseases , Medical University of South Carolina , Charleston , SC , USA., Hurst JM; a Department of Pharmacy , Medical University of South Carolina , Charleston , SC , USA ;; b Division of Infectious Diseases , Medical University of South Carolina , Charleston , SC , USA., Boger MS; b Division of Infectious Diseases , Medical University of South Carolina , Charleston , SC , USA., Gnann JW Jr; b Division of Infectious Diseases , Medical University of South Carolina , Charleston , SC , USA.
Jazyk: angličtina
Zdroj: Infectious diseases (London, England) [Infect Dis (Lond)] 2016 Oct; Vol. 48 (10), pp. 732-7. Date of Electronic Publication: 2016 May 19.
DOI: 10.1080/23744235.2016.1185533
Abstrakt: Background: Early appropriate antibiotic selection is associated with favorable clinical outcomes. We evaluated the clinical impact of rapid detection of vancomycin-resistant Enterococcal bacteremia (VREB) by the FilmArray blood culture identification (BCID) panel coupled with antimicrobial stewardship program (ASP) interventions.
Methods: Hospitalized adult patients with VREB identified by conventional methods (CM) were compared to patients with VREB identified by BCID. Real time alerts of BCID results were provided to the ASP for intervention. Outcomes were compared between groups.
Results: Sixty-eight patients with VREB were included (CM, n = 45; BCID, n = 23). No significant differences in demographics, pre-existing conditions, or clinical characteristics were observed. Significant reductions were demonstrated between CM and BCID groups in median hours to organism identification (47.7 versus 18.2, p < 0.001), to identification of vancomycin resistance from time of culture positivity (50.1 versus 1.2, p < 0.001), and time to effective therapy (50.3 versus 20.8, p < 0.001). Differences between CM and BCID did not reach statistical significance for mortality (35.6% versus 26.1%), 30-day readmission rate (31.0% versus 17.6%), intensive care length of stay [LOS] (8.0 versus 7.0 days), post-culture LOS (14.6 versus 14.1 days) or median hospital costs per patient ($95,826 versus $53,195).
Conclusions: In patients with VREB, rapid organism and resistance detection by the BCID panel with ASP intervention significantly reduced time to initiation of effective therapy by over 24 hours. Non-significant improvements in clinical outcomes were observed. Additional studies are needed to determine the full implications of BCID technology on patient outcome.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje